Abstract:

Objective To observe the application effect of local cold compress in pegylated liposomal doxorubicin(PLD)induced hand-foot syndrome(HFS)from a clinical perspective. Methods During June 2021 to June 2023, a non-synchronous randomized controlled trial was conducted to recruit breast cancer(BC) patients who received chemotherapy with a PLD in the Department of Breast Surgery, Affiliated Hospital of Hebei Engineering University as the research objects, they were randomized to the routine care group (from June 2021 to May 2022, n=58) or local cold compress group (from June 2022 to June 2023, n=55). The incidence of HFS, treatment compliance, satisfaction and medical experience of the patients were included as comparisons between groups. Results The incidence of HFS in the local cold compress group was significantly lower than that of the routine care group (23.6% [13/55] vs 44.8% [26/58], χ²=5.609, P=0.018). The severity of HFS in the local cold compress group was significantly lighter than that of the routine care group (P<0.05). The incidence of HFS of grade II and above in the local cold compress group was significantly lower than that of the routine care group (10.9% vs 25.9%, P<0.05). The treatment compliance and satisfaction of patients in the local cold compress group were significantly higher than those of the routine care group (P<0.05).Conclusion Local cold compress can effectively prevent the incidence and reduce and severity of HFS in chemotherapy with a PLD,and it is capable of improving the treatment compliance and satisfaction of patients.

Key words: hand, foot and mouth disease, local cold compress, breast cancer, pegylated liposomal doxorubicin